Insights into the molecular targets and emerging
pharmacotherapeutic interventions for nonalcoholic fatty liver
disease

J 2022

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ, Giovanni TARANTINO et. al.

Basic information

Original name

Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease

Authors

NEGI, Chander Kant (356 India, belonging to the institution), Pavel BABICA (203 Czech Republic, guarantor, belonging to the institution), Lola Murielle BAJARD ÉP.ESNER (250 France, belonging to the institution), Julie DOBROVOLNÁ (203 Czech Republic, belonging to the institution) and Giovanni TARANTINO (380 Italy)

Edition

Metabolism: Clinical and Experimental, USA, W. B. Saunders Company, 2022, 0026-0495

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30202 Endocrinology and metabolism

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 9.800

RIV identification code

RIV/00216224:14310/22:00119691

Organization unit

Faculty of Science

DOI

http://dx.doi.org/10.1016/j.metabol.2021.154925

UT WoS

000718929100007

Keywords in English

Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Drug therapy; Clinical trials; Novel targets

Abstract

V originále

Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.

Links

EF17_043/0009632, research and development project

Name: CETOCOEN Excellence

GA19-19143S, research and development project

Name: 3-dimenzionální in vitro modely jater pro studium chronické hepatotoxicity a jaterních onemocnění indukovaných sinicovými toxiny.

Investor: Czech Science Foundation

LM2018121, research and development project

Name: Výzkumná infrastruktura RECETOX (Acronym: RECETOX RI)

Investor: Ministry of Education, Youth and Sports of the CR, RECETOX RI

Citovat

NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ and Giovanni TARANTINO. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism: Clinical and Experimental. USA: W. B. Saunders Company, 2022, vol. 126, January 2022, p. 1-18. ISSN 0026-0495. Available from: https://dx.doi.org/10.1016/j.metabol.2021.154925.

@article{1838661,
   author = {Negi, Chander Kant and Babica, Pavel and Bajard ép.Esner, Lola Murielle and Dobrovolná, Julie and Tarantino, Giovanni},
   article_location = {USA},
   article_number = {January 2022},
   doi = {http://dx.doi.org/10.1016/j.metabol.2021.154925},
   keywords = {Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH); Drug therapy; Clinical trials; Novel targets},
   language = {eng},
   issn = {0026-0495},
   journal = {Metabolism: Clinical and Experimental},
   title = {Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease},
   url = {https://www.sciencedirect.com/science/article/pii/S0026049521002250?via%3Dihub},
   volume = {126},
   year = {2022}
}

TY  - JOUR
ID  - 1838661
AU  - Negi, Chander Kant - Babica, Pavel - Bajard ép.Esner, Lola Murielle - Dobrovolná, Julie - Tarantino, Giovanni
PY  - 2022
TI  - Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease
JF  - Metabolism: Clinical and Experimental
VL  - 126
IS  - January 2022
SP  - 1-18
EP  - 1-18
PB  - W. B. Saunders Company
SN  - 00260495
KW  - Nonalcoholic fatty liver disease (NAFLD)
KW  - Nonalcoholic steatohepatitis (NASH)
KW  - Drug therapy
KW  - Clinical trials
KW  - Novel targets
UR  - https://www.sciencedirect.com/science/article/pii/S0026049521002250?via%3Dihub
N2  - Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease worldwide. With no Food and Drug Administration approved drugs, current treatment options include dietary restrictions and lifestyle modification. NAFLD is closely associated with metabolic disorders such as obesity, type 2 diabetes, and dyslipidemia. Hence, clinically various pharmacological approaches using existing drugs such as antidiabetic, anti-obesity, antioxidants, and cytoprotective agents have been considered in the management of NAFLD and nonalcoholic steatohepatitis (NASH). However, several pharmacological therapies aiming to alleviate NAFLD-NASH are currently being examined at various phases of clinical trials. Emerging data from these studies with drugs targeting diverse molecular mechanisms show promising outcomes. This review summarizes the current understanding of the pathogenic mechanisms of NAFLD and provides an insight into the pharmacological targets and emerging therapeutics with specific interventional mechanisms. In addition, we also discuss the importance and utility of new approach methodologies and regulatory perspectives for NAFLD-NASH drug development.
ER  -

NEGI, Chander Kant, Pavel BABICA, Lola Murielle BAJARD ÉP.ESNER, Julie DOBROVOLNÁ and Giovanni TARANTINO. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. \textit{Metabolism: Clinical and Experimental}. USA: W. B. Saunders Company, 2022, vol.~126, January 2022, p.~1-18. ISSN~0026-0495. Available from: https://dx.doi.org/10.1016/j.metabol.2021.154925.

Detailed Information on Publication Record